MEI Pharma Bets on Litecoin, Backed by $100M Investment, Pioneers Corporate Crypto Strategy
July 18, 2025
MEI Pharma is making a strategic move into cryptocurrency by investing in Litecoin, choosing it over Bitcoin and Ethereum, as part of a broader trend among corporations diversifying their treasury assets.
This initiative is backed by a $100 million private placement investment from GSR, which is also managing MEI's treasury assets to support this new strategy.
The private placement involves selling approximately 29.2 million shares at $3.42 per share, expected to close around July 22, 2025, with the funds dedicated to acquiring Litecoin as MEI's primary treasury reserve.
This marks the first instance of a public company aligning its treasury strategy with Litecoin at an institutional level, signaling growing confidence in the cryptocurrency.
Litecoin, often called 'silver to Bitcoin's gold,' has maintained 100% uptime since its creation in 2011 and is recognized for its stability and utility in retail and payment platforms.
The move is supported by the Litecoin Foundation, which emphasizes the legitimacy and broader adoption of Litecoin in corporate finance.
GSR's involvement aims to unlock the potential of digital assets while managing associated risks, reflecting a broader institutional interest in cryptocurrencies.
This development aligns with recent surges in Ethereum's value and increased institutional demand, indicating a shift towards mainstream acceptance of digital assets.
Analysts predict that if market conditions remain favorable, Litecoin could see its price increase significantly, potentially up to tenfold by 2026, driven by institutional interest.
The strategy also highlights a changing attitude in conservative sectors, with more companies recognizing the benefits of blockchain technology and cryptocurrencies.
Litecoin founder Charlie Lee expressed enthusiasm about this milestone, emphasizing the growing institutional confidence in Litecoin's stability and principles of speed, security, and decentralization.
Overall, this move by MEI Pharma and GSR signifies a notable step toward the mainstream adoption of cryptocurrencies within corporate finance, potentially increasing liquidity and stability in the digital asset market.
Summary based on 10 sources
Get a daily email with more Crypto stories
Sources

Investing.com • Jul 18, 2025
MEI Pharma stock soars after announcing $100 million Litecoin treasury strategy
HackerNoon • Jul 18, 2025
GSR Leads $100M Private Placement Into MEI Pharma To Launch First Litecoin Treasury Strategy